Eva Martinez-Ojinaga
Overview
Explore the profile of Eva Martinez-Ojinaga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuesta-Martin de la Camara R, Bravo-Garcia Morato M, Camara-Hijon C, Magallares L, Martinez-Ojinaga E, Gonzalez-Torbay A, et al.
Pediatr Allergy Immunol
. 2024 Oct;
35(10):e14259.
PMID: 39418167
No abstract available.
2.
Roman E, Barrio J, Cilleruelo M, Torres R, Almazan V, Coronel C, et al.
An Pediatr (Engl Ed)
. 2024 Oct;
101(4):267-277.
PMID: 39396896
Coeliac disease is a common condition for which the only current treatment is a gluten-free diet. Adherence to this diet is not always easy and is associated with a reduction...
3.
Martinez Gallego M, Crespo Sanchez M, Serrano Olmedo M, Buno Soto A, Alvarez Casasempere S, Nozal P, et al.
Nutrients
. 2024 Mar;
16(5).
PMID: 38474812
Celiac disease (CeD) is an autoimmune condition triggered by gluten in genetically predisposed individuals, affecting all ages. Intestinal permeability (IP) is crucial in the pathogenesis of CeD and it is...
4.
Castillejo G, Ochoa-Sangrador C, Perez-Solis D, Cilleruelo M, Donat E, Garcia-Burriel J, et al.
Nutrients
. 2023 Mar;
15(5).
PMID: 36904266
The worldwide prevalence of asymptomatic coeliac disease (CD) is increasing, which is in part due to the routine screening of children with risk factors. Both symptomatic and asymptomatic patients with...
5.
Sanchez-Valverde F, Martinez-Ojinaga E, Donat E, Bodas A, Bandres E, Torres R, et al.
Hum Immunol
. 2023 Mar;
84(4):290-295.
PMID: 36858916
Celiac disease is strongly associated with HLA DQ, specifically with haplotypes. DRB1*03-DQA1*05:01/DQB1*02:01 (DQ2.5),DRB1*07-DQA1*02:01/DQB1*02:02 (DQ2.2), DRB1*11-DQA1*05:05/DQB1*03:01 (DQ7.5), and DRB1*04-DQA1*03:01/DQB1*03:02 (DQ8). The distribution of these risk haplotypes in patients with celiac disease...
6.
Donat E, Roca M, Castillejo G, Sanchez-Valverde F, Garcia-Burriel J, Martinez-Ojinaga E, et al.
J Pediatr Gastroenterol Nutr
. 2022 Sep;
75(6):743-748.
PMID: 36123770
Objectives: The objective of this study was to assess the association between serological markers and changes of the intestinal mucosa in children with celiac disease (CD). Methods: Clinical data from...
7.
Cabrerizo M, Hidalgo-Montes I, Mendez-Echevarria A, Rodrieguez-Pena R, Ruiz-Carrascoso G, Martinez-Ojinaga E, et al.
Pediatr Allergy Immunol
. 2022 Aug;
33(8):e13834.
PMID: 36003052
No abstract available.
8.
Tan I, Coutinho de Almeida R, Modderman R, Stachurska A, Dekens J, Barisani D, et al.
Front Immunol
. 2021 Dec;
12:734763.
PMID: 34950132
Background & Aims: Celiac disease (CeD), an immune-mediated disease with enteropathy triggered by gluten, affects ~1% of the general European population. Currently, there are no biomarkers to predict CeD development....
9.
Salvador-Martin S, Kaczmarczyk B, Alvarez R, Navas-Lopez V, Gallego-Fernandez C, Moreno-Alvarez A, et al.
Pharmaceutics
. 2021 Jan;
13(1).
PMID: 33429950
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic...
10.
Salvador-Martin S, Bossacoma F, Pujol-Muncunill G, Navas-Lopez V, Gallego-Fernandez C, Viada J, et al.
J Pediatr Gastroenterol Nutr
. 2020 Aug;
71(4):508-515.
PMID: 32773718
Objectives: Inflammatory bowel disease (IBD) is more complex in children and they will have to live with the disease for much longer. For this reason, it is necessary to optimize...